Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RUDN University bacteriophage cocktail
- Development stage
- Unknown
- Lead developer
- University Clinical Hospital n.a. V.V. Vinogradov
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
This bacteriophage cocktail is an experimental therapeutic consisting of 3-4 virulent phages for each targeted bacterial species. It is being evaluated as an adjunct to standard antibiotic therapy for the treatment of infective endocarditis (IE). The cocktail is designed to target a broad range of pathogens commonly associated with IE, including *Staphylococcus spp.*, *Streptococcus spp.*, *Enterococcus spp.*, and several Gram-negative "Non-HACEK" organisms like *E. coli* and *P. aeruginosa*. By utilizing the natural lytic cycle of bacteriophages, the treatment aims to eradicate bacteria, including those that are multi-drug resistant or protected within biofilms on heart valves. The therapy is currently being investigated in a Phase 3 clinical trial sponsored by the University Clinical Hospital named after V.V. Vinogradov, a branch of the RUDN University.
- Other names
- BacteriophagePhage Therapy in Infective Endocarditis
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on RUDN University bacteriophage cocktail.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RUDN University bacteriophage cocktail.